Zoetis Becomes Fully Independent Company June 24

Zoetis Inc., the former animal health business of Pfizer Inc., marked its separation from Pfizer on June 24, its first day as fully independent company.

“This is an historic day for Zoetis,” said Zoetis CEO Juan Ramón Alaix. “We are setting off on the next stage in our company’s life—pursuing our own initiatives and strategies as a fully independent company.”

As of today, according to the terms of the exchange offer that commenced on May 22, Pfizer has accepted shares of Pfizer stock in exchange for all of its 400,985,000 shares of Zoetis common stock, according to the preliminary results of its exchange offer announced in a Pfizer press release today. Following Pfizer’s acceptance of shares of Pfizer common stock, Pfizer no longer holds any ownership interest in Zoetis, making Zoetis a fully independent company.

Full details of the preliminary results are available in a separate press release issued this morning by Pfizer and on www.zoetisexchange.com. Final results of the exchange offer will be announced in the coming days.

The company generated annual revenues of $4.3 billion in 2012, has more than 9,300 employees around the world and 29 manufacturing facilities in 11 countries. It provides products for veterinarians, livestock producers, and people who raise and care for livestock and companion animals in 120 countries. For the horse industry, Zoetis provides equine vaccines, dewormers, and sedative analgesics.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More